101 related articles for article (PubMed ID: 19353808)
1. Antinociceptive interactions of micro- and kappa-opioid agonists in the colorectal distension assay in rats.
Briggs SL; Rech RH
Pharmacol Biochem Behav; 2009 Apr; 92(2):343-50. PubMed ID: 19353808
[TBL] [Abstract][Full Text] [Related]
2. Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.
Minervini V; Lu HY; Padarti J; Osteicoechea DC; France CP
Psychopharmacology (Berl); 2018 Aug; 235(8):2245-2256. PubMed ID: 29785554
[TBL] [Abstract][Full Text] [Related]
3. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
4. Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats.
Briggs SL; Rech RH; Sawyer DC
Pharmacol Biochem Behav; 1998 Jun; 60(2):467-72. PubMed ID: 9632230
[TBL] [Abstract][Full Text] [Related]
5. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists.
Carey GJ; Bergman J
J Pharmacol Exp Ther; 2001 Apr; 297(1):215-23. PubMed ID: 11259547
[TBL] [Abstract][Full Text] [Related]
6. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.
Minervini V; Dahal S; France CP
J Pharmacol Exp Ther; 2017 Feb; 360(2):280-287. PubMed ID: 27903642
[TBL] [Abstract][Full Text] [Related]
7. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
Negus SS; Schrode K; Stevenson GW
Exp Clin Psychopharmacol; 2008 Oct; 16(5):386-99. PubMed ID: 18837635
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Pitts RC; Dykstra LA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1501-8. PubMed ID: 7996463
[TBL] [Abstract][Full Text] [Related]
9. Additive antinociceptive effects of mixtures of the κ-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats.
Maguire DR; France CP
Behav Pharmacol; 2016 Feb; 27(1):69-72. PubMed ID: 26292184
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
Picker MJ; Dykstra LA
J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
[TBL] [Abstract][Full Text] [Related]
11. Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.
Hayes AG; Skingle M; Tyers MB
Br J Pharmacol; 1986 Aug; 88(4):867-72. PubMed ID: 3017495
[TBL] [Abstract][Full Text] [Related]
12. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
Gatch MB; Negus SS; Mello NK; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1282-9. PubMed ID: 8819513
[TBL] [Abstract][Full Text] [Related]
13. Kappa agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms.
Valdez GR; Platt DM; Rowlett JK; Rüedi-Bettschen D; Spealman RD
J Pharmacol Exp Ther; 2007 Nov; 323(2):525-33. PubMed ID: 17702903
[TBL] [Abstract][Full Text] [Related]
14. Chronic sucrose intake augments antinociception induced by injections of mu but not kappa opioid receptor agonists into the periaqueductal gray matter in male and female rats.
Kanarek RB; Mandillo S; Wiatr C
Brain Res; 2001 Nov; 920(1-2):97-105. PubMed ID: 11716815
[TBL] [Abstract][Full Text] [Related]
15. Involvement of kappa-opioid receptors in visceral nociception in mice.
Larsson MH; Bayati A; Lindström E; Larsson H
Neurogastroenterol Motil; 2008 Oct; 20(10):1157-64. PubMed ID: 18643891
[TBL] [Abstract][Full Text] [Related]
16. Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test.
Chen X; Geller EB; Adler MW
Eur J Pharmacol; 2007 Feb; 557(1):32-6. PubMed ID: 17173891
[TBL] [Abstract][Full Text] [Related]
17. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
Steinmiller CL; Young AM
Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
[TBL] [Abstract][Full Text] [Related]
19. Further characterization of the discriminative stimulus effects of spiradoline.
Holtzman SG
Pharmacol Biochem Behav; 2000 Jul; 66(3):517-22. PubMed ID: 10899364
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
Paronis CA; Waddell AB; Holtzman SG
Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
